|
 |
|
|
|
| |
|
|
|
|
| Table 6. HIV-infected patients currently prescribed highly active antiretroviral therapy (HAART) by data source and insurance status* |
|
|
|
|
View PDF
|
|
Data in Tables 6-8 are based on the following analyses:
- Among patients eligible according to guidelines in place in 1999, what is the proportion of patients prescribed highly active antiretroviral therapy1 (HAART) in ASD in 1999 and SHDC in 1998?
|
 |
|
|
|
|
|
|
|
|
|
|
|
| Data Source |
Total |
|
Private |
|
Public |
|
No Insurance |
| % |
Treated/
Eligible |
% |
Treated/
Eligible |
% |
Treated/
Eligible |
% |
Treated/
Eligible |
| ASD |
61 |
2,298/3,751 |
|
64 |
762/1,184 |
|
60 |
1,223/2,054 |
|
61 |
313/513 |
| SHDC Site A |
68 |
166/242 |
66 |
69/105 |
75 |
79/104 |
57 |
22/38 |
| SHDC Site B |
64 |
111/171 |
75 |
33/44 |
54 |
39/72 |
65 |
36/55 |
| SHDC Site C |
69 |
161/249 |
80 |
166/83 |
75 |
98/131 |
27 |
9/33 |
|
|
|
|
*Persons with unknown insurance status were not included.
|
- Overall, 61-69% of all eligible patients were prescribed HAART as defined by 1999 guidelines.
- Prescription of HAART was greater among patients with private insurance for all data sources except SHDC Site A.
- HAART prescription for patients with no insurance was substantially lower for SHDC Site C compared with the other SHDC sites and ASD. This may be due to the populations represented by the samples at the 3 SHDC sites (see Technical Notes). Sites A and B may contain more providers in and near metropolitan
areas who routinely provide HIV-related care and may be more likely to prescribe HAART regardless of the patient’s insurance status.
- Data from the SHAS and MOPTB studies were not available for this question.
|
|
|
| 1 |
HAART was defined as two nucleoside analogue reverse transcriptase inhibitors (zidovudine+didanosine, zalcitabine or lamivudine or stavudine+didanosine or lamivudine) plus at least one protease inhibitor (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir) or non-nucleoside analogue reverse transcriptase inhibitor (delavirdine, efavirenz, nevirapine).[2]
|
|
|
|
|
|
|
|
|
|
